CAY10499: Precision Lipase Inhibition for Lipid Immunometabolic Research

Introduction: Integrating Lipid Metabolism and Immune Microenvironment

Lipid metabolism has emerged as a critical regulator of immune cell function and disease pathology. Enzymes like hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) orchestrate the mobilization and signaling functions of lipids, impacting processes from energy homeostasis to the differentiation of immune cells. CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, offers unique precision for dissecting these pathways, especially in the context of emerging links between lipid regulation and immunosuppression in diseases such as hepatocellular carcinoma.

Mechanism of Action: Selectivity and Potency of CAY10499

CAY10499 is a crystalline small molecule designed to selectively target critical nodes in lipid metabolism. It potently inhibits MGL-mediated hydrolysis of 4-nitrophenyl acetate (4-NPA) with an IC50 of 0.5 ± 0.03 μM (source: product_spec). Its action extends to human recombinant fatty acid amide hydrolase (FAAH), which it fully inhibits at an IC50 of 76 nM, and to recombinant human HSL, with an IC50 of 90 nM (source: product_spec). These values highlight CAY10499’s high efficacy and selectivity for its lipase targets, while its minimal displacement of [3H]-CP-55940 binding to CB1 and CB2 cannabinoid receptors ensures that endocannabinoid receptor signaling is largely unperturbed (source: product_spec).

HSL catalyzes the hydrolysis of tri-, di-, and monoacylglycerols as well as cholesterol esters, not only mobilizing fatty acids for energy but also influencing processes like steroidogenesis, spermatogenesis, and foam cell formation (source: product_spec). MGL, meanwhile, is central to the catabolism of 2-arachidonoylglycerol (2-AG), a key endocannabinoid that modulates physiological processes including immune signaling.

Protocol Parameters

• assay: MGL-mediated 4-NPA hydrolysis | value: IC50 = 0.5 ± 0.03 μM | applicability: Lipid metabolism assay reagent for in vitro enzymatic studies | rationale: Enables precise quantitation of MGL inhibition | source_type: product_spec
• assay: FAAH-mediated [3H]-AEA hydrolysis | value: IC50 = 76 nM | applicability: Enzyme inhibitor screening for fatty acid amide hydrolase activity | rationale: Distinguishes CAY10499’s selectivity profile | source_type: product_spec
• assay: Recombinant human HSL inhibition | value: IC50 = 90 nM | applicability: Inhibitor for steroidogenesis research and fatty acid mobilization studies | rationale: Highly relevant for dissecting HSL-dependent lipid signaling | source_type: product_spec
• assay: Solubility in DMSO | value: ≥32.4 mg/mL | applicability: Preparation of concentrated stocks for biochemical assays | rationale: Facilitates use in diverse assay formats | source_type: product_spec
• assay: Working solution stability | value: Short-term at -20°C | applicability: Workflow planning for time-sensitive experiments | rationale: Ensures compound integrity | source_type: product_spec
• assay: In vivo applications | value: Not validated | applicability: Excluded from diagnostic or therapeutic protocols | rationale: For research use only | source_type: workflow_recommendation

Reference Insight Extraction: EV-Transferred Lipogenic Enzymes in Tumor Immunometabolism

The pivotal study by Liu et al. (2026), published in Advanced Science, unveils a novel mechanism by which tumor-derived extracellular vesicles (EVs) transfer ATP-citrate lyase (ACLY) to monocytes, triggering their differentiation into immunosuppressive tumor-associated macrophages (TAMs) (see paper). These TAMs exhibit distinct immune-inhibitory features, contributing to immune evasion and hepatocellular carcinoma (HCC) progression. Crucially, the study demonstrates that blocking EV-transferred ACLY—using targeted inhibitors—restrains TAM-induced immunosuppression and enhances immunotherapeutic efficacy, particularly in combination with checkpoint blockade.

This paradigm provides a practical framework for researchers: when evaluating the immunometabolic impact of lipase inhibitors like CAY10499, it becomes vital to consider not only direct enzymatic inhibition but also the broader metabolic rewiring of macrophages and their microenvironment. The reference thus underscores the need for selective, potent inhibitors that can dissect these interconnected axes of lipid metabolism and immune regulation.

Comparative Analysis: How CAY10499 Advances Standard Lipase Assays

Existing articles have thoroughly addressed the utility of CAY10499 in conventional lipid metabolism and cell-based workflows (see SW033291.com), as well as its role in macrophage-focused metabolic control (see PalonosetronAPI.com). These works offer practical guidance on assay design and highlight CAY10499’s robustness in modulating HSL and MGL activities. However, the current piece advances the field by emphasizing the translational value of precise, selective inhibition in unraveling the metabolic underpinnings of immune suppression—especially where EV-derived enzymes like ACLY intersect with lipase-driven pathways.

Unlike prior content, this article focuses on the implications of lipase inhibitors for dissecting the metabolic programming of immune cells in complex disease environments, guided by the latest mechanistic insights from tumor immunology. This approach complements technical workflow recommendations with a deeper theoretical foundation, making it invaluable for researchers designing next-generation immunometabolic studies.

Advanced Applications: CAY10499 in Immunometabolic and Disease-Relevant Assays

The selectivity profile and solubility characteristics of CAY10499 make it a superior enzyme inhibitor for fatty acid mobilization studies and research tool for atherosclerosis. Its application extends beyond basic lipid metabolism assays to advanced models where lipid signaling intersects with immune cell differentiation and disease pathogenesis. For example, in the context of hepatocellular carcinoma, CAY10499 can be deployed to clarify how lipase activity shapes monocyte-to-macrophage transitions, particularly in the presence of tumor-derived metabolic cues.

Moreover, CAY10499 enables the precise interrogation of steroidogenesis by inhibiting HSL-dependent cholesterol ester hydrolysis, a process relevant to endocrine research and metabolic syndrome models. Its minimal off-target engagement with cannabinoid receptors ensures that observed effects are attributable to lipase inhibition rather than confounding endocannabinoid signaling.

Researchers can leverage CAY10499 as a lipid metabolism assay reagent to distinguish between direct enzymatic effects and broader immunometabolic rewiring, as illuminated by the EV-ACLY paradigm (see ChelerythrineChloride.com). This positions CAY10499 not only as a tool for traditional lipid assays, but as a bridge to advanced immunometabolic research and therapeutic discovery.

Why This Cross-Domain Matters, Maturity, and Limitations

The intersection of lipid metabolism and immune modulation is rapidly maturing as a research frontier, especially in oncology and metabolic disease. The mechanistic insights from EV-transferred ACLY studies demonstrate that metabolic enzymes, including those targeted by CAY10499, have profound effects on immune cell differentiation and function in the tumor microenvironment. However, while the utility of CAY10499 is well-established in vitro and in ex vivo models, its application in in vivo immunotherapy protocols remains to be validated (source: workflow_recommendation). Researchers should thus interpret findings within the scope of preclinical and mechanistic studies, using CAY10499 primarily as a research tool rather than a therapeutic candidate.

Product Formulation and Handling: Ensuring Experimental Rigor

CAY10499 is supplied as a crystalline solid (molecular weight 355.3, chemical formula C18H17N3O5), optimized for stability at -20°C (source: product_spec). It is highly soluble in DMSO (≥32.4 mg/mL) and ethanol (≥8.93 mg/mL), but insoluble in water, making it suitable for most biochemical and cell-based assay platforms. For consistent results, it is recommended that solutions be prepared fresh and used short-term, as long-term storage in solution may compromise integrity (source: product_spec).

As with all APExBIO reagents, CAY10499 is intended strictly for scientific research use, not for diagnostic or medical applications. Its high purity and well-characterized activity profiles support reproducible data generation across diverse lipid and immunometabolic studies.

Conclusion and Future Outlook

CAY10499 stands at the forefront of lipid immunometabolic research, enabling unprecedented precision in the inhibition of human hormone sensitive lipase and monoglyceride lipase. By integrating advanced mechanistic insights—such as those from the EV-transferred ACLY study (see paper)—researchers can now design assays that not only quantify enzymatic activity, but also illuminate the metabolic crosstalk underlying immune suppression and disease progression. As the field advances, compounds like CAY10499 will be essential for bridging classic biochemistry with translational immunology, supporting both hypothesis-driven research and the development of new immunometabolic intervention strategies.

This article extends the groundwork laid by prior content (see YT Broth 2x Liquid), which showcased CAY10499’s performance in tumor microenvironment assays, by providing a broader conceptual framework for its application in immunometabolic research. Through this integrated perspective, CAY10499 is poised to remain an indispensable asset for researchers at the cutting edge of lipid and immune cell biology.